Outpatient chemotherapy with S-1 for recurrent head and neck cancer

Taku Yamashita, Seiichi Shinden, Takahisa Watabe, Akihiro Shiotani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer. Patients and Methods: S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly. Results: The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1% for 12 months and 17.5% for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2%). Most adverse events were mild (up to grade 2). Conclusion: S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.

Original languageEnglish
Pages (from-to)577-581
Number of pages5
JournalAnticancer Research
Volume29
Issue number2
Publication statusPublished - 2009 Feb
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Outpatients
docetaxel
Drug Therapy
Therapeutics
Survival Rate
Retrospective Studies
Quality of Life
Safety
Survival
Neoplasms

Keywords

  • Low dose chemotherapy
  • Outpatient chemotherapy
  • Recurrent head and neck cancer
  • S-1
  • Tumor dormancy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yamashita, T., Shinden, S., Watabe, T., & Shiotani, A. (2009). Outpatient chemotherapy with S-1 for recurrent head and neck cancer. Anticancer Research, 29(2), 577-581.

Outpatient chemotherapy with S-1 for recurrent head and neck cancer. / Yamashita, Taku; Shinden, Seiichi; Watabe, Takahisa; Shiotani, Akihiro.

In: Anticancer Research, Vol. 29, No. 2, 02.2009, p. 577-581.

Research output: Contribution to journalArticle

Yamashita, T, Shinden, S, Watabe, T & Shiotani, A 2009, 'Outpatient chemotherapy with S-1 for recurrent head and neck cancer', Anticancer Research, vol. 29, no. 2, pp. 577-581.
Yamashita T, Shinden S, Watabe T, Shiotani A. Outpatient chemotherapy with S-1 for recurrent head and neck cancer. Anticancer Research. 2009 Feb;29(2):577-581.
Yamashita, Taku ; Shinden, Seiichi ; Watabe, Takahisa ; Shiotani, Akihiro. / Outpatient chemotherapy with S-1 for recurrent head and neck cancer. In: Anticancer Research. 2009 ; Vol. 29, No. 2. pp. 577-581.
@article{f82498bf52f740f8b19970c964ff6653,
title = "Outpatient chemotherapy with S-1 for recurrent head and neck cancer",
abstract = "Background: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer. Patients and Methods: S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly. Results: The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1{\%} for 12 months and 17.5{\%} for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2{\%}). Most adverse events were mild (up to grade 2). Conclusion: S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.",
keywords = "Low dose chemotherapy, Outpatient chemotherapy, Recurrent head and neck cancer, S-1, Tumor dormancy",
author = "Taku Yamashita and Seiichi Shinden and Takahisa Watabe and Akihiro Shiotani",
year = "2009",
month = "2",
language = "English",
volume = "29",
pages = "577--581",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2",

}

TY - JOUR

T1 - Outpatient chemotherapy with S-1 for recurrent head and neck cancer

AU - Yamashita, Taku

AU - Shinden, Seiichi

AU - Watabe, Takahisa

AU - Shiotani, Akihiro

PY - 2009/2

Y1 - 2009/2

N2 - Background: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer. Patients and Methods: S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly. Results: The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1% for 12 months and 17.5% for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2%). Most adverse events were mild (up to grade 2). Conclusion: S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.

AB - Background: This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer. Patients and Methods: S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly. Results: The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1% for 12 months and 17.5% for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2%). Most adverse events were mild (up to grade 2). Conclusion: S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.

KW - Low dose chemotherapy

KW - Outpatient chemotherapy

KW - Recurrent head and neck cancer

KW - S-1

KW - Tumor dormancy

UR - http://www.scopus.com/inward/record.url?scp=61449213174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449213174&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 577

EP - 581

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2

ER -